Lohmann A, Grobara P, Dingler E
Department of Pharmacokinetics, Thiemann Arzneimitte GmbH, Waltrop, Fed. Rep. of Germany.
Arzneimittelforschung. 1991 Nov;41(11):1164-7.
The concomitant application of magnesium-aluminium-hydroxide gel does not influence the absorption of vinpocetine (CAS 42971-09-5). The pharmacokinetics of vinpocetine under the influence of a concomitant application of magnesium-aluminium-hydroxide gel was investigated. 18 healthy male volunteers were included in the study. Vinpocetine was administered in the galenic form of a film-coated tablet in a dosage of 20 mg t.i.d. over 10 days. On days 5 and 6 of the study, blood samples were taken at 16 different moments over 24 h and analyzed as to their vinpocetine content. Starting with the 6th day of the study, the patients were administered in addition 1 sachet of an magnesium-aluminium-hydroxide gel 4 times a day. On day 9 of the trial, blood samples were taken again over 24 h. The parameters examined were AUC, Cmin, Cmax, tmax and Mean Residence Time. The results as to these parameters of day 5 were compared with those of day 9. As a further parameter, apovincaminic acid plasma levels were determined. There was no difference as to the vinpocetine amount absorbed with or without concomitant application of magnesium-aluminium-hydroxide gel. Apovincaminic acid plasma levels were lowered by approx. 11% when associated with the antacid.
同时服用氢氧化镁铝凝胶不会影响长春西汀（CAS 42971-09-5）的吸收。研究了同时服用氢氧化镁铝凝胶对长春西汀药代动力学的影响。18名健康男性志愿者参与了该研究。长春西汀以薄膜包衣片的剂型给药，剂量为20mg，每日三次，共服用10天。在研究的第5天和第6天，在24小时内的16个不同时间点采集血样，并分析其中长春西汀的含量。从研究的第6天开始，患者额外每天服用4次1包氢氧化镁铝凝胶。在试验的第9天，再次在24小时内采集血样。检测的参数包括AUC、Cmin、Cmax、tmax和平均驻留时间。将第5天这些参数的结果与第9天的结果进行比较。作为另一个参数，测定了阿朴长春胺酸的血浆水平。无论是否同时服用氢氧化镁铝凝胶，长春西汀的吸收量均无差异。与抗酸剂联用时，阿朴长春胺酸的血浆水平降低了约11%。
